WilliamJefferyEdenfieldMD

Oncology • Greenville, SC

Breast Cancer, Hematologic Oncology, Hospice & Palliative, Neuro-Oncology

Medical Director, Institute for Translational Oncology Research Greenville Health System Cancer Institute

Join to view full profile

Dr. Edenfield is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Edenfield's full profile

Already have an account?

Office
900 W Faris Rd
Greenville, SC 29605
Phone+1 864-679-3900

Fax+1 864-679-3901

Education & Training

National Capital ConsortiumFellowship, Hematology and Medical Oncology, 1995 - 1998
National Capital ConsortiumResidency, Internal Medicine, 1992 - 1995
University of Miami Leonard M. Miller School of MedicineClass of 1992

Certifications & Licensure

SC State Medical License 2003 - 2025
FL State Medical License 1994 - 2005
NC State Medical License 1999 - 2004
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013

Clinical Trials

A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Mar 01
Completed
Phase 1
Gemzar, Cisp, Sunitinib Urothelial Ca Start of enrollment: 2008 Aug 01
Completed
Phase 2
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2011 Mar 01
Completed
Phase 3
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
Terminated
Phase 3
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01
Completed
Phase 1, Phase 2
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2
A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer Start of enrollment: 2012 Dec 01
Terminated
Phase 2
A Study of BBI608 in Adult Patients With Advanced Malignancies Start of enrollment: 2009 Mar 01
Completed
Phase 1
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer Start of enrollment: 2012 Mar 01
Completed
Phase 2
A Study of BBI503 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2012 Feb 01
Completed
Phase 1
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Start of enrollment: 2014 Jan 01
Completed
Phase 1, Phase 2
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors Start of enrollment: 2016 Dec 01
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
Mats Någård, Mei-Lin Ah-See, James Strauss, Trisha Wise-Draper, Howard P Safran
Cancer Chemotherapy and Pharmacology. 2023-09-01
Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.
Mats Någård, Mei-Lin Ah-See, James Strauss, Trisha Wise-Draper, Howard P Safran
Cancer Chemotherapy and Pharmacology. 2023-08-01
1 citations
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.
Benjamin J Bulen, Nickolay A Khazanov, Daniel H Hovelson, Laura E Lamb, Marc Matrana
Cancer Research Communications. 2023-07-01

Lectures

Selected reaction monitoring mass spectrometry (SRM-MS) evaluation of HER2 equivocal breast cancer.
ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member